Construction Of Vectors For The Overexpression Of Recombinant Human Growth Hormone In Bacillus Megaterium

Bagi mengekspreskan gen hGH di dalam Bacillus megaterium, 3 konstrak telah direka. Konstrak-konstrak ini dinamakan sebagai Construct 1 (M7hGH), Construct 2 (R2L4sphGH) dan Construct 3 (spBsubhGH). Construct 1 direka dengan memasukkan gen pengawalatur (kodon penamat, tapak perlekatan ribosom, jujukan TAACA dan kodon pemula) yang akan diekspreskan di dalam sel. Manakala Construct 2 telah dicipta untuk diekpreskan di luar sel yang mana mengandungi isyarat peptida daripada Bacillus brevis dan gen. In order to express the hGH gene in Bacillus megaterium, 3 constructs were designed. The constructs were named as Construct 1 (M7hGH), Construct 2 (R2L4sphGH) and Construct 3 (spBsubhGH). Construct 1 was designed with regulatory features [stop codon, ribosome binding site (RBS), TAACA sequence and start codon] meant for intracellular expression. Construct 2, was created to express human growth hormone (hGH) extracellularly by using the signal peptide from Bacillus brevis

Preventive effects of Polygonum minus essential oil on cisplatin-induced hepatotoxicity in sprague dawley rats

Cisplatin is a chemotherapeutic agent widely used in treating various types of cancer. However, its usage is restricted due to the adverse hepatoxicity, as seen in approximately 36% of cancer patients receiving cisplatin treatment. Polygonum minus essential oil has high antioxidant capacity, and is enriched with terpenoids and phenolic compounds. The objective of this study was to investigate effects of P. minus essential oil (PmEO) supplementation on cisplatin-induced hepatotoxicity in rats. Male rats were divided into seven different groups, namely: control (C), cisplatin-induced (CP), positive control with β-caryophyllene 150 mg/kg (BCP), PmEO 100 mg/kg (PmEO100CP), PmEO 200 mg/kg (PmEO200CP), PmEO 400 mg/kg (PmEO400CP) and PmEO 400 mg/kg alone (PmEO400). PmEO and BCP was given orally for 14 days prior to a single dose cisplatin (10 mg/kg) injection on day 15 and rats were sacrificed on day 18. Liver enzymes, histology, ultrastructural morphology and oxidative stress markers such as glutathione, glutathione peroxidase, catalase, superoxide dismutase and malondialdehyde were assayed. Compared to controls, levels of transaminase enzymes, serum bilirubin and oxidative stress were all increased in CP, PmEO200CP and PmEO400CP groups. However, only PmEO100CP and BCP groups reduced these increases in level of transaminase enzymes and oxidative stress compared to CP group. On both light microscopic and ultrastructural examination, CP and PmEO400CP groups showed hepatotoxicity, exhibited by cytoplasmic vacuolation, congested blood sinusoids and increased number of Kupffer cells. However, these changes were minimized in the PmEO100CP group. Therefore, we concluded that PmEO given at 100 mg/kg has preventive effect against cisplatin-induced hepatotoxicity in rats

Polygonum minus essential oil modulates cisplatin-induced hepatotoxicity through inflammatory and apoptotic pathways

Oxidative stress, inflammation and apoptosis are thought as primary mediators of cisplatin-induced hepatotoxicity. The objective of this study was to determine the protective effect of Polygonum minus essential oil in cisplatin-induced hepatotoxicity. A total of forty-two male rats were randomly divided into seven groups: control, cisplatin, β-caryophyllene 150 mg/kg (BCP), PmEO 100 mg/kg + cisplatin (PmEO100CP), PmEO 200 mg/kg + cisplatin (PmEO200CP), PmEO 400 mg/kg + cisplatin (PmEO400CP) and PmEO 400 mg/kg (PmEO400). Rats in the BCP, PmEO100CP, PmEO200CP, PmEO400CP and PmEO400 group received respective treatment orally for 14 consecutive days prior to cisplatin injection. All animals except for those in the control group and PmEO400 were administered with a single dose of cisplatin (10 mg/kg) intraperitoneally on day 15 and all animals were sacrificed on day 18. PmEO100CP pretreatment protected against cisplatin-induced hepatotoxicity by decreasing CYP2E1 and indicators of oxidative stress including malondialdehyde, 8-OHdG and protein carbonyl which was accompanied by increased antioxidant status (glutathione, glutathione peroxidase, superoxide dismutase and catalase) as compared to cisplatin group. PmEO100CP pretreatment also modulated changes in liver inflammatory markers (TNF-α, IL-1α, IL-1β, IL-6 and IL-10). PmEO100CP administration also notably reduced cisplatin-induced apoptosis significantly as compared to cisplatin group. In conclusion, our results suggested that P. minus essential oil at a dose of 100 mg/kg may protect against cisplatin-induced hepatotoxicity possibly via inhibition of oxidative stress, inflammation and apoptosis

Therapeutic Potential of Honey and Propolis on Ocular Disease

Honey and propolis have recently become the key target of attention for treating certain diseases and promoting overall health and well-being. A high content of flavonoids and phenolic acids found in both honey and propolis contributes to the antioxidant properties to scavenge free radicals. Honey and propolis also exhibited antibacterial effects where they act in two ways, namely the production of hydrogen peroxide (H2O2) and gluconic acids following the enzymatic activities of glucose oxidase, which exerts oxidative damage on the bacteria. Additionally, the anti-inflammatory effects of honey and propolis are mainly by reducing proinflammatory factors such as interleukins and tumor necrosis factor alpha (TNF-α). Their effects on pain were discovered through modulation at a peripheral nociceptive neuron or binding to an opioid receptor in the higher center. The aforementioned properties of honey have been reported to possess potential therapeutic topical application on the exterior parts of the eyes, particularly in treating conjunctivitis, keratitis, blepharitis, and corneal injury. In contrast, most of the medicinal values of propolis are beneficial in the internal ocular area, such as the retina, optic nerve, and uvea. This review aims to update the current discoveries of honey and propolis in treating various ocular diseases, including their antioxidant, anti-inflammatory, antibacterial, and anti-nociceptive properties. In conclusion, research has shown that propolis and honey have considerable therapeutic promise for treating various eye illnesses, although the present study designs are primarily animal and in vitro studies. Therefore, there is an urgent need to translate this finding into a clinical setting